Arrowhead Pharmaceuticals Corp (ARWR) Misses Q1 EPS by 41c, Revenues Miss
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $82.00 +0.22%
EPS Growth %: +4.8%
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +4.8%
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Corp (NASDAQ: ARWR) reported Q1 EPS of $0.13, $0.41 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $34.66 million versus the consensus estimate of $71.6 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Corp (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU approves Arrowhead's plozasiran for rare triglyceride disorder
- Alphabet slides over 6% as AI brain drain and SpaceX slump converge
- Hermès can regain momentum despite China weakness, Jefferies says
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
